This report was first published by Endpoints News. To see the original version, click here
The FDA unveiled long-awaited draft guidance on how biopharma companies can validate new approaches for toxicology and other early-phase safety studies, potentially reducing the animal testing that’s long been used to assess the risks of experimental drugs for humans.
In some circumstances, the new tools could “replace animal testing while advancing predictive toxicology using human-centric methods,” according to the eight-page document released Wednesday.
您已阅读27%（549字），剩余73%（1452字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。